 The study sample will be composed of 325 women, younger than 50 years of age, with histologically confirmed primary breast cancer stages: T1 - T4, N0 - N1 and M0. All women will have been premenopausal at the time of diagnosis, have completed adjuvant chemotherapy with the exception of herceptin, which can continue to receive a minimum of 4 months and a maximum of 5 years prior to study entry. Women may currently be receiving adjuvant hormonal therapy. All women should be disease-free at time of study entry. Potentially eligible women will be screened for the presence of at least one of the following 3 menopausal symptoms during the previous 2-month period: hot flushes, sweating andor vaginal dryness. 